<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARAFATE
								- sucralfate suspension </strong><br>Aptalis Pharma Inc.<br></p></div>
<h1>CARAFATE (sucralfate) Suspension</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CARAFATE Suspension contains sucralfate and sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex.</p>
<div class="Figure"><img alt="Carafate suspension structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb67b1c-b4c0-46f2-8a81-df1510e006aa&amp;name=carafate-structure.jpg"></div>
<p>CARAFATE Suspension for oral administration contains 1 g of sucralfate per 10 mL.</p>
<p>CARAFATE Suspension also contains: colloidal silicon dioxide NF, FD&amp;C Red #40, flavor, glycerin USP, methylcellulose USP, methylparaben NF, microcrystalline cellulose NF, purified water USP, simethicone USP, and sorbitol solution USP. Therapeutic category: antiulcer.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical-pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sucralfate is only minimally absorbed from the gastrointestinal tract.  The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.</p>
<p>Although the mechanism of sucralfate’s ability to accelerate healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:</p>
<ol>
<li>Studies in human subjects and with animal models of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease have shown that sucralfate forms an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>-adherent complex with proteinaceous exudate at the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> site.</li>
<li>In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions.</li>
<li>In human subjects, sucralfate given in doses recommended for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> therapy inhibits pepsin activity in gastric juice by 32%.</li>
<li>In vitro, sucralfate adsorbs bile salts.</li>
</ol>
<p>These observations suggest that sucralfate’s antiulcer activity is the result of formation of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>-adherent complex that covers the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clinical-trials"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">In a multicenter, double-blind, placebo-controlled study of CARAFATE Suspension, a dosage regimen of 1 g (10 mL) four times daily was demonstrated to be superior to placebo in <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing. </p>
<a name="table1"></a><table>
<caption><span>Results From Clinical Trials Healing Rates for Acute <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></span></caption>
<tfoot>
<tr class="First Last"><td class="Footnote" align="left"> </td></tr>
<tr class="Last"><td class="Footnote" align="left"></td></tr>
<tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd> P=0.016</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd> P=0.001</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd> P=0.0001</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td>Treatment</td>
<td>n </td>
<td>Week 2 Healing Rates</td>
<td>Week 4 Healing Rates</td>
<td>Week 8 Healing Rates</td>
</tr>
<tr>
<td>CARAFATE Suspension</td>
<td>145</td>
<td>23(16%)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> </td>
<td>66(46%)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td>95(66%) <a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
<tr class="Last">
<td>Placebo</td>
<td>147 </td>
<td>10(7%)</td>
<td>39(27%) </td>
<td>58(39%)</td>
</tr>
</tbody>
</table>
<p> Equivalence of sucralfate suspension to sucralfate tablets has not been demonstrated. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications-usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CARAFATE (sucralfate) Suspension is indicated in the short-term (up to 8 weeks) treatment of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CARAFATE is contraindicated for patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to the active substance or to any of the excipients.  </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The physician should read the "PRECAUTIONS" section when considering the use of CARAFATE in pregnant or pediatric patients, or patients of childbearing potential. </p>
<p><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal ulcer</span> is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration.</p>
<p>Episodes of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported in diabetic patients. Close monitoring of glycemia in diabetic patients treated with sucralfate suspension is recommended. Adjustment of the anti-diabetic treatment dose during the use of sucralfate suspension might be necessary.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="special-populations"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold Underline">Special Populations: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Chronic Renal Failure</span> and Dialysis Patients</span></h2>
<p class="First">When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract.  Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum.  Patients with normal renal function receiving the recommended doses of sucralfate and aluminum-containing products adequately excrete aluminum in the urine.  Patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> or those receiving dialysis have impaired excretion of absorbed aluminum.  In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum <span class="product-label-link" type="condition" conceptid="75924" conceptname="Osteodystrophy">osteodystrophy</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>) have been described in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Sucralfate should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="drug-interactions"></a><a name="section-6.2"></a><p></p>
<h2><span class="Underline">Drug Interactions</span></h2>
<p class="First">Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline.  Subtherapeutic <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with the addition of sucralfate to chronic warfarin therapy.</p>
<p>The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract.  In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction.  Due to CARAFATE's potential to alter the absorption of some drugs, CARAFATE should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="carcinogenesis"></a><a name="section-6.3"></a><p></p>
<h2><span class="Underline">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Chronic oral toxicity studies of 24 months’ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose).</p>
<p>There was no evidence of drug-related tumorigenicity.  A reproduction study in rats at doses up to 38 times the human dose did not reveal any  indication of fertility impairment.  Mutagenicity studies were not conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="pregnancy"></a><a name="section-6.4"></a><p></p>
<h2><span class="Underline">Pregnancy</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="teratogenic"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold">Teratogenic effects. Pregnancy Category B.</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursing-mothers"></a><a name="section-6.5"></a><p></p>
<h2><span class="Underline">Nursing Mothers</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-6.6"></a><p></p>
<h2><span class="Underline">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-6.7"></a><p></p>
<h2><span class="Underline">Geriatric Use</span></h2>
<p class="First">Clinical studies of CARAFATE Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <span class="Bold"><a href="#dosage-administration">DOSAGE AND ADMINISTRATION</a></span>)</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (See <span class="Bold"><a href="#special-populations">PRECAUTIONS Special Populations: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Chronic Renal Failure</span> and Dialysis Patients</a></span>). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse-reactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions to sucralfate tablets in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate, adverse effects were reported in 129 (4.7%).</p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gastric <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Bold">Post-marketing</span> cases of hypersensitivity have been reported with the use of sucralfate suspension, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the mouth, <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.   </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> and respiratory tract <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been reported with an unknown oral formulation of sucralfate. </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported with sucralfate</p>
<p><span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">Bezoars</span> have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to <span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">bezoar</span> formation (such as <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span>) or were receiving concomitant enteral tube feedings.</p>
<p>Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate is <span class="Bold">not</span> intended for intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose.  Sucralfate is only minimally absorbed from the gastrointestinal tract.  Risks associated with acute overdosage should, therefore, be minimal.  In rare reports describing sucralfate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage-administration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span>.</span> The recommended adult oral dosage for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> is 1 g (10 mL/2 teaspoons) four times per day. CARAFATE should be administered on an empty stomach.</p>
<p>Antacids may be prescribed as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> but should not be taken within one-half hour before or after sucralfate.</p>
<p>While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.</p>
<p><span class="Bold">Elderly:</span> In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See <span class="Bold"><a href="#geriatric">PRECAUTIONS Geriatric Use</a></span>).</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to Aptalis Pharma US, Inc. at 1-800-472-2634 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="how-supplied"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CARAFATE (sucralfate) Suspension 1 g/10 mL is a pink suspension supplied in bottles of 14 fl oz (NDC 58914-170-14).</p>
<p></p>
<p><span class="Bold">SHAKE WELL BEFORE USING. AVOID FREEZING.</span></p>
<p>Store at controlled room temperature 20-25°C (68-77°F)[see USP].</p>
<p></p>
<p>Rx Only</p>
<p>Prescribing Information rev. March 2013</p>
<p>Aptalis Pharma US, Inc.</p>
<p>100 Somerset Corporate Boulevard</p>
<p>Bridgewater, NJ 08807</p>
<p>USA</p>
<p>CARAFATE<span class="Sup">® </span>is a reg﻿istered trademark of Aptalis Pharma Canada Inc., which is an affiliate of Aptalis Pharma US, Inc.</p>
<p><a href="http://www.aptalispharma.com/">www.aptalispharma.com</a></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Carafate Suspension, Bottle<br><br><img alt="Carafate bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb67b1c-b4c0-46f2-8a81-df1510e006aa&amp;name=carafate-suspension-14oz.jpg"><br>Carafate Suspension, Box - Sample<br><img alt="Carafate box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb67b1c-b4c0-46f2-8a81-df1510e006aa&amp;name=carafate-suspension-6x10box.jpg"><br><br>
            Carafate Suspension, Foil - Sample<br><br><img alt="Carafate foil" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb67b1c-b4c0-46f2-8a81-df1510e006aa&amp;name=carafate-suspension-6x10foil.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARAFATE
								 		
					</strong><br><span class="contentTableReg">sucralfate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-170</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sucralfate</strong> (Sucralfate) </td>
<td class="formItem">Sucralfate</td>
<td class="formItem">1 g  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">0.004 mg  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem">87.92 mg  in 10 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem">1.78 mg  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sorbitol</strong></td>
<td class="formItem">177.62 mg  in 10 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">618.006 mg  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (Maraschino Cherry Artificial Flavor #2359) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-170-14</td>
<td class="formItem">414 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:58914-170-60</td>
<td class="formItem">6  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">295.7 mL in 1 CUP, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019183</td>
<td class="formItem">12/16/1993</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aptalis Pharma Inc.
							(033555307)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Aventis US, Inc.</td>
<td class="formItem"></td>
<td class="formItem">783243835</td>
<td class="formItem">MANUFACTURE(58914-170), pack(58914-170), analysis(58914-170)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f47cc79f-d18e-4395-8189-7645bf572741</div>
<div>Set id: 0fb67b1c-b4c0-46f2-8a81-df1510e006aa</div>
<div>Version: 8</div>
<div>Effective Time: 20140424</div>
</div>
</div> <div class="DistributorName">Aptalis Pharma Inc.</div></p>
</body></html>
